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ABSTRACT  
Systemic and airway eosinophilia are recognised features of asthma. There are, however, patients who exhibit 
discordance between local and systemic eosinophilia. In this study, we sought to determine the prevalence and 
characteristics of patients with concordant and discordant systemic and bronchial eosinophilia. 
We conducted a retrospective study on 508 asthmatics with successful sputum induction. We assessed the 
relationship between blood and sputum eosinophils by breaking down the population into four groups according 
to blood (≥400 cells per mm3) and sputum (≥3%) eosinophils. Then, we prospectively reassessed the link 
between eosinophils and asthma control (Asthma Control Questionnaire (ACQ)) and exacerbation rate in a new 
cohort of 250 matched asthmatics. 
In our retrospective cohort, asthmatics without eosinophilic inflammation were the largest group (49%). The 
group with isolated sputum eosinophilia (25%) was, compared with noneosinophilic asthma, associated with 
lower forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity ratio and higher bronchial 
hyperresponsiveness and exhaled nitric oxide fraction (FeNO). Asthmatics exhibiting isolated systemic 
eosinophilia (7%) had similar characteristics as noneosinophilic asthmatics. The group with concordant systemic 
and airway eosinophilia (19%) showed remarkable male predominance, and had the lowest airway calibre, ACQ 
score and quality of life, and the highest bronchial hyperresponsiveness, FeNO and exacerbation rate. The 
prospective cohort confirmed the different subgroup proportions and the higher ACQ and exacerbation rates in 
cases of diffuse eosinophilia compared with noneosinophilic asthmatics. 
Concomitant systemic and bronchial eosinophilic inflammation contribute to poor asthma control. 
 
Introduction 
Bronchial asthma is a complex airway inflammatory disease. The eosinophilic feature is recognised as a pivotal 
trait of the disease [1]. The technique of induced sputum has been instrumental in assessing the proportion of 
eosinophilic asthma. It is now accepted that eosinophilic asthma, defined as a sputum eosinophil count of 2-3% 
or higher, represents slightly less than half of the asthmatic population [2-5]. 
In asthma, sputum eosinophil count correlates with blood eosinophil count [4, 6-8] and blood eosinophil count is 
considered as a good surrogate marker for sputum eosinophil count (over 2-3% with a cut-off of 220 cells per 
mm
3
 or 3%) [4, 9]. However, the sensitivity and specificity of blood eosinophils to predict a sputum eosinophil 
proportion of  ≥3% are <80%, and there are patients who show discordance between local and systemic 
inflammation. 
There is a huge controversy about the role of eosinophils as a key player in asthma severity [10-21]. Some 
studies have looked at airway eosinophils in bronchoalveolar lavage (BAL) [21], induced sputum [11, 12, 14, 
16-18] and bronchial biopsies [19, 20], while others focused on systemic inflammation through blood eosinophil 
count measurement [20]. Discrepancies between studies may be linked to the different compartments sampled 
and, for some of the studies, to the limited number of subjects investigated. 
While inhaled corticoids, the recommended mainstay treatment of asthma, have been consistently shown to 
reduce airway eosinophilic inflammation and improve asthma control [22], their effect on systemic eosinophilia 
was shown to be rather weak at usual doses [23]. By contrast, the new biologicals directed towards interleukin-5 
were shown to dramatically decrease circulating blood eosinophils, an effect that was associated with the 
reduction of asthma exacerbation [24] and improvement in asthma control [25]. 
To the best of our knowledge, there has never been detailed investigation of the relationship between blood and 
sputum eosinophil in a large population of asthmatics. In this study, we sought to determine whether looking at 
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blood and sputum eosinophilic inflammation might help in our understanding of asthma severity. We first 
retrospectively investigated the demographic, functional and symptomatic features of 508 asthmatics classified 
according to systemic and local eosinophilic inflammation, and then prospectively validated the relationship 
between asthma control and eosinophilic inflammation in a new cohort of 250 patients well matched to our 
retrospective cohort with respect to demographic, functional and treatment characteristics. 
 
Material and methods  
Subject characteristics 
We conducted a retrospective study on a series of 508 patients with asthma recruited from the University Asthma 
Clinic of Liege, Liege, Belgium, between October 1, 2005 and June 27, 2011. The patients came from routine 
practice to University Hospital, Liege, and were recruited by two clinicians involved in asthma. Entry criteria 
were any patients with asthma aged ≥ 18 years who agreed to undergo detailed investigation at the asthma clinic. 
The visits were not parts of an asthma trial. All the patients who had a successful sputum induction were 
included in the study. Their demographic and functional characteristics are summarised in tables 1 and 2. 
Asthma was diagnosed based on the presence of chronic respiratory symptoms such as cough, breathlessness or 
dyspnoea together with the demonstration of airflow variability. The latter was defined by airway 
hyperresponsiveness shown by one or more of the following: increase in forced expiratory volume in 1 s (FEV1) 
of >12% and 200 mL following inhalation of 400 µg salbutamol; or inhaled concentration of methacholine 
provoking a 20% fall in FEV1 of <16 mg∙mL-1. Methacholine challenge was performed according to a 
standardised methodology as previously described [26]. Subjects were characterised as atopic if they had at least 
one positive specific IgE test (>0.35 kU∙L-1; Phadia, Groot-Bijgaarden, Belgium) for at least one common 
aeroallergen (cat, dog, house dust mites, grass pollen, tree pollen and a mixture of moulds). 
Exacerbation in the previous year was defined by a course of oral corticoids for ≥ 3 days for a case of asthma 
worsening. Nasal polyps and sinusitis was diagnosed by an ear, nose and throat physician either by endoscopy or 
sinus computed tomography. Gastro-oesophageal reflux was diagnosed either by symptoms of pyrosis at history 
taking or the presence of oesophagitis demonstrated by gastroscopy. 
Study design 
Patients underwent exhaled nitric oxide fraction (FeNO) measurement at a flow rate of 50 mL∙s-1 according to the 
European Respiratory Society (ERS)/American Thoracic Society (ATS) recommendations (NIOX; Aerocrine, 
Solna, Sweden). FeNO was first measured and followed by spirometry with bronchodilation, sputum induction 
and blood sampling. All tests were performed on the same day. 
Quality of life was assessed using the self-administered Asthma Quality of Life Questionnaire [27] and asthma 
control by the Asthma Control Questionnaire (ACQ) of JUNIPER et al. [28]. 
Sputum was induced and processed as previously reported [29], and was successful in 78% of the patients 
encountered in our asthma clinic, which is similar to previous reports [30, 31]. Cell count were estimated on 
samples centrifuged (cytospin) and stained with Diff-Quick after counting 500 cells (Dade, Brussels, Belgium). 
Prospective study validation 
To validate the results of the retrospective analysis of the link between asthma control and eosinophilic 
inflammation, we conducted a prospective study. 
A new cohort of 250 consecutive patients was recruited from routine practice between June 30, 2011 and January 
12, 2013. None of these patients had been included in the retrospective cohort. Their demographic, functional 
and treatment characteristics were similar to the retrospective population (tables 1 and 2). 
Exacerbation rate for the prospective population was measured through a telephone call over a period of 12 
months following the visit to the asthma clinic, during which treatment was initiated or adjusted according to 
asthma control, lung function and inflammatory markers at the discretion of the clinician. 13 patients were lost to 
follow-up and in the 17 patients in whom the observation period was <1 year, we calculated the annualised 
exacerbation rate. 
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TABLE 1 Demographic, control and treatment characteristics for the whole population 
Characteristics Retrospective cohort Prospective cohort 
Subjects n 508 250 
Males/females n 201/307 99/151 
Age years 52 (19-88] 50 (16-85) 
Age of onset   
   <12 years 24 22 
   12-40 years 37 36 
   ≥ 40 years 39 42 
Height cm 167 ± 9 168 ± 9 
Weight kg 74 ±16 73 ± 17 
Atopy yes/no (%) 296/212 [58] 148/102 (59) 
Current smokers 101 (20) 55 (22) 
   Exposure pack-years 22 (0.5-60) 25 (2-60) 
Ex-smokers 99 (19) 38 (15) 











Rhinitis 58 56 






 0.86 ± 2.02
++
 
LABA 319 (63) 141 (56) 
LTRA 93 (18) 50 (20) 
Theophylline 16(3) 11 (4) 
ICS   
   Steroid naïve 153 (30) 82 (33) 
   Low dose
||
 73 (14) 35 (14) 
   Moderate dose
+
 138 (27) 63 (25) 
   High dose
§
 144 (28) 70 (28) 
Oral corticosteroids 32(6) 25 (10) 
Data are presented as median (range), %, mean ± SD or n (%), unless otherwise stated. Exacerbations were evaluated during the year prior to 
the visit. LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist; ICS: Inhaled corticosteroids. High dose: >1000 µg∙day
-1 
beclomethasone. #: during the year prior to the visit; || : ≤500 µg per day beclomethasone; +: 500-1000 µg per day beclomethasone; §: 
>1000µg per day beclomethasone; f : n = 174; ##: n = 273; || || ; n=428; ++: n = 237. *: p<0.05. 
 
 
TABLE 2 Functional and inflammatory characteristics for the whole population 
Characteristics Retrospective cohort Prospective cohort 
FEV1 % predicted 84 ±19 82 ± 21 
FEV1/FVC % 73 ± 11 71 ± 15* 
PC20 mg∙mL-1 geometric mean (range) 3.20 (0.025-16) 2.92 (0.05-16) 
Reversibility % 11 ± 14 9±10 
ACQ score 2.01 ± 1.38 2.00 ± 1.25 
AQLQ score 4.61 ± 1.35 4.46 ± 1.39 
Blood eosinophil count cells per mm
3
 230 (0-3220) 188 (0-1133)* 
FeNO ppb 27 (0-247) 25 (4-348) 
Sputum eosinophils % 2 (0-94) 2.8 (0-90) 
Sputum neutrophils % 45 (0-100) 49 (0-100) 
Data are presented as mean ± SD or median (range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital 
capacity; PC20: provocative concentration of methacholine causing a 20% fall in FEV1; ACQ: Asthma Control Questionnaire; AQLQ: 
Asthma Quality of Life Questionnaire; FeNO: exhaled nitric oxide fraction. *: p<0.05. 
 
Statistical analyses 
We used blood eosinophil count and sputum eosinophil percentage to subdivide our asthmatic population into 
four groups. The chosen blood (≥ 400 cells per mm3) and sputum (≥ 3%) threshold values were considered as the 
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limit of abnormality by our routine laboratory. The results were expressed as mean ± SD or mean ± SEM for 
continuous variables; median (range) was preferred for skewed distributions. For categorical variables, the 
number of observations and percentages are given in each category. Comparisons between different subgroups 
were performed with a Kruskal-Wallis test. The Spearman correlation coefficient was used to measure the 
association between clinical parameters. 
Power calculations indicated a required total sample size of 250 subjects to confirm a change in ACQ score ≥0.5 
between noneosinophilic asthmatics and patients exhibiting diffuse eosinophilic inflammation, with a power of 
80%. The results were considered to be significant at the 5% critical level (p<0.05). 
 
Results 
The demographic, functional and inflammatory characteristics of the retrospective cohort of asthmatics (n=508), 
classified according to their blood (threshold 400 cells per mm
3
) [25] and sputum eosinophil counts (threshold 
3%), are described in tables 3-5. The patients without evidence of eosinophilic inflammation represented the 
largest group, accounting for 49% of the cohort. Those patients with selective airway eosinophilic inflammation 
came second, accounting for 25% of the patients, whereas those exhibiting the reverse picture were much less 
numerous, only representing 7%. Patients combining systemic and airway eosinophilic inflammation account for 
19% of the patients. 
The inhaled corticoids treatment regimen was similar between subgroups (table 3). 
Compared with noneosinophilic asthmatics, the characteristics of patients exhibiting isolated sputum 
eosinophilia were a higher proportion of males and atopic subjects, higher total serum IgE levels, lower FEVl 
and FEVl/forced vital capacity ratio, and higher bronchial hyperresponsiveness and reversibility to β2-agonists 
(fig. 1, and tables 4 and 5). As for patients with high levels of blood eosinophils without sputum eosinophilia, 
they had a higher total serum IgE compared with noneosinophilic asthmatics (fig. 1 and table 5). The presence of 
both local and systemic eosinophilic inflammation was strikingly more frequent in males, and associated with 
the greatest lung function impairment, and the lowest asthma control (mean ≥ SEM ACQ score 2.54+1.45 versus 
1.88+1.39; mean difference 0.66, 95% CI -0.99--0.32 (p=0.0001)) (figs 1 and 2) and quality of life (table 4). 
They also had the highest FeNO while those with eosinophilia in only one compartment had similar, intermediate 
FeNO. Noneosinophilic asthmatics had the lowest FeNO, comparable to that found in healthy subjects (fig. 3 and 
table 5). 
Patients with increased sputum eosinophilia reported greater numbers of severe exacerbations in the previous 
year, and this was particularly the case for those displaying concordant systemic and airway eosinophilia (table 
3). Likewise, the proportion of sinusitis and nasal polyps was clearly raised in eosinophilic asthmatics while 
there was no difference regarding the gastro-oesophageal reflux (table 3). 
In patients treated with high doses of inhaled corticosteroids (n=144), the proportions of the different subgroups 
were similar to those found in the whole cohort, and the subgroup exhibiting both bronchial and systemic 
eosinophilic inflammation had the highest exacerbation rate and the poorest lung function (table 6). 
In order to validate the relationship between poor asthma control and comprehensive eosinophilic inflammation, 
we prospectively recruited a population of 250 asthmatics whose demographic, functional and inflammatory 
characteristics were similar to our retrospective cohort (table 1 and 2). In this population, we found similar 
proportions of patients in the different subgroups (47% were patients without evidence of eosinophilic 
inflammation, 32% exhibited isolated sputum eosinophilia, 4% had isolated systemic eosinophilia and 17% 
combined systemic and airway eosinophilia) and confirmed that patients with both systemic and airway 
eosinophilic inflammation had poorer asthma control compared with noneosinophilic asthma (mean ± SEM ACQ 
score 2.23 ± 1.40 versus 1.79±1.12; mean difference 0.44, 95% CI 0.007-0.89 (p<0.05)) (fig 2). 
In the prospective cohort, patients exhibiting diffuse eosinophilic inflammation had a higher number of 
exacerbations in the year prior to the visit to the asthma clinic (mean ± SD 1.11 ± 1.65, n=41) than 
noneosinophilic patients (mean ± SD 0.77 ± 2.55, n=111) (p<0.05). Interestingly, for the whole cohort, the 
exacerbation rate over the 12 months following the asthma clinic visit decreased compared with that occurring in 
the year before (mean 0.86 ± 2.02 (95% CI 0.61-1.12) versus mean 0.50±1.18 (95% CI 0.35-0.65) after) 
(p=0.015) (see the online supplementary material for all details on ACQ score and exacerbation rate in the 
prospective cohort). Moreover, in the year following the visit to the asthma clinic, the number of exacerbations 
was significantly higher in patients advised to take high-dose ICS (mean ± SD 1.06 ± 1.63, n=93) than in those 
advised to take low (mean ± SD 0.17 ± 0.62, n=58) or moderate (mean ± SD 0.15 ± 0.40, n=55) doses of ICS or 
not to take ICS at all (0 ± 0, n=31) (p<0.0001). 
When pooling both the retrospective and the prospective cohort (n = 758), there was a weak but significant 
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relationship between ACQ and sputum eosinophil count (r=0.16, p<0.0001) but not between blood eosinophils 
and ACQ (r=0.02, p=0.57) (fig .4). 
 
TABLE 3 Retrospective cohort: demographic and treatment characteristics of asthmatics (n = 508) according 
to blood and sputum eosinophil count 



















≥400 cells per mm3, 
sputum eosinophils 
≥3% 
Subjects 249 (49] 128 (25) 34(7) 97 (19) 
Males/females n 78/171 54/74* 16/18 53/44*** 
Age years 52 (21-86) 53 (21-88) 51 (21-85) 51 (19-86) 
Age of onset     
   <12years 22.6 27.6 26.5 23.3 
   12-40 years 34.5 36.2 32.3 45.6 
   ≥ 40 years 42.9 36.2 41.2 31.1 
Height cm 166 ± 9 168 ± 9 169 ± 9 169 ± 9 
Weight kg 73 ± 16 74±15 76 ± 17 75 ± 17 
BMI kg∙m-2 26.3 ± 5 26.4 ± 5 26.3 ± 4.8 26.4 ± 5.3 
Atopy yes/no (%) 126/123 (51) 82/46 (64)* 22/12 (65) 66/31 (68)** 
Current smokers 54 (22) 29 (23) 6(18) 12 (12)* 
Bronchiectasis
||, +
 19 13 17 26 
Gastro-oesophageal 
reflux 
77 81 86 77 
Nasal polyposis
§
 9 25*** 37*** 43*** 
Sinusitis
§, f
 34 38 42 61*** 




0.42 + 0.9 0.93 + 2.72* 0.59 + 0.98 1.5 + 2.5*** 
ICS     
   Steroid naïve 82 (33) 31 (24) 9 (26) 31 (32) 
   Low dose
|| ||
 30 (12) 20 (16) 5 (15) 18 (19) 
   Moderate
++
 70 (28) 37 (29) 11 (32) 20 (21) 
   High dose
§§
 67 (271 40 (31)* 9 (26) 28 (29) 
Data are presented as n (%), median (rangel, % or mean± SD, unless otherwise stated. BMI: body mass index; ICS: inhaled corticosteroids. #: 
comparator group; ||: n=174; +: based on chest computed tomography (CT); §: based on sinus CT and nasal endoscopy; f-. n=273; ##: during 
the year prior to the visit; || || : <500µg per day beclomethasone; ++: 500-1000 µg per day beclomethasone; §§: >1000µg per day 
beclomethasone. 
*: p<0.05; **: p<0.01 ; ***: p<0.001. 
 
Discussion 
The original finding of this study is that patients exhibiting both local and systemic eosinophilic inflammation 
had more severe asthma reflected by lower baseline lung function, higher bronchial responsiveness to 
methacholine, poorer asthma control and quality of life, and a greater number of exacerbations in the previous 
year. This suggests that the global magnitude of eosinophilic inflammation is a significant factor in disease 
severity. 
Another new finding of this study is that it provides figures on the proportion of asthmatics classified according 
to the site of eosinophilic inflammation. Overall, asthmatics without any sign of eosinophilic inflammation 
account for almost half of the patients while one-quarter to one-third had selective airway eosinophilia. Patients 
with systemic and airway eosinophilic inflammation represent one-fifth of the patients those with isolated 
systemic eosinophilic inflammation are rather rare. These proportions are found irrespective of asthma treatment 
received including high doses of inhaled corticoids. We believe our new classification based on eosinophilic 
inflammation is pertinent to the clinician and goes in line with the need to phenotype severe asthmatics as 
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TABLE 4 Retrospective cohort: functional characteristics, asthma control and quality of life of asthmatics (n = 
508) according to blood and sputum eosinophil count 






















FEV1 % predicted 87±19 83 ± 20* 84 ± 23 75 ± 19*** 
FEV1/FVC % 75 ± 10 72 ± 9* 77±10 71 ± 10*** 
TLC % predicted 101 ± 16 101± 20 92 ± 21 103 ± 15 
FRC % predicted 109 ± 29 108 ± 20 97 ± 30 101 ± 18 




3.99 (0.05-16) 2.32 (0.025-16)* 4.53 (0.05-16) 1.49 (0.05-16)** 
Reversibility % 8 ± 9 13 ± 14* 9 ± 12 17 ± 16*** 
ACQ score 1.88 ± 1.39 1.87 ± 1.19 1.98 ± 1.5 2.54 ± 1.45*** 
<0.75 58 (23) 26 (20) 7 (21) 10 (10)** 
0.75-1.5 45 (18) 30 (23) 10 (29) 15 (15) 
>1.5 146 (59) 72 (56) 17 (50) 72 (74)* 
AQLQ score 4.67±1.36 4.84±1.3 4.47±1.26 4.3 ± 1.4* 
Data are presented as mean + SD or n (%), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: 
total lung capacity; FRC: functional residual capacity; KCO: transfer coefficient of the lung for carbon monoxide; PC20: provocative 
concentration of methacholine causing a 20% fall in FEV1; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life 
Questionnaire. #: comparator group. 
*: p<0.05; **: p<0.01; ***: p<0.001. 
 
TABLE 5 Retrospective cohort: inflammatory characteristics of asthmatics (n = 508) according to blood and 
sputum eosinophil count 
 Blood eosinophils 























IgE kU∙L-1 87 (1-7338) 211 (3-6 785)*** 180 (13-2329)* 225 (1-17183)*** 
Blood eosinophils % 1.7 (0-5.4) 3.2 (0-7)*** 6 (0.3-15)*** 8 (0.4-30)*** 
Blood eosinophils per mm
3
 140 (0-380) 250 (0-390)*** 490 (400-1220)*** 590 (400-3220)*** 
Blood neutrophils % 59 (27-82) 57 (34-91) 57 (41-76) 52 (32-67)*** 
Blood neutrophils per mm
3
 4180 (76-11080) 4370 (2290-15410) 5040 (1760-10010) 3965 (1820-8670) 
Sputum eosinophils % 0.3 (0-2.9) 9 (3-79)*** 0.6 (0-2.8) 26 (3.2-94)*** 
Sputum eosinophils per mm
3
 2.7 (0-1020) 70 (6-5226)*** 4.8 (0-1796) 287 (5-33 375)*** 
Sputum neutrophils % 58 (0-1001 39 (0-90)*** 57 (0.2-99) 30 (0.2-91)*** 




422 (0-73 440) 334 (1-9588) 560 (14-160 974) 259 (1-15441) 
Fibrinogen g L
-1
 3.2 (1.9-10) 3 (2-6) 3.3 (2.6-5) 3.4 (2.2-7) 
CRP mg∙L-1 1.7 (0.2-10) 2 (0.2-14) 1.4 (0.5-4) 1.6 (0.2-13) 
FeNO ppb 17 (0-192) 37 (2-222]*** 32 (5-93)** 77 (11-247)*** 
Data are presented as median (range). CRP: C-reactive protein; FeNO: exhaled nitric oxide. #: comparator group. *: p<0.05; **: p<0.01; ***: 
p<0.001. 
 
As mentioned, the link between eosinophils and asthma severity has been extensively debated. The first attempts 
to investigate this relationship were based on sampling BAL or biopsies during bronchoscopy. The invasive 
nature of the procedure has obviously limited the number of subjects studied, which may have led to contrasting 
results because of the interindividual patient variability. Being less invasive, the technique of induced sputum 
has considerably widened the series of patients investigated and has been key to the emergence of recognition of 
several inflammatory asthma phenotypes. Previous studies found higher levels of sputum eosinophil counts in 
uncontrolled asthmatics [17, 33]. Another study showed that patients with high blood eosinophilia (>250 cells 
per mm
3
) had lower FEV1 values and worse asthma control than those with normal blood eosinophil counts [34]. 
Recently, VOLBEDA et al. [20] have shown that patients with uncontrolled asthma exhibit higher eosinophil 
numbers in peripheral blood and a trend for a higher eosinophil count in induced sputum, but they did not 
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provide detailed analysis on the discordance between blood and airway eosinophilia. Here, in our retrospective 
cohort, we found that patients exhibiting eosinophilic inflammation both in blood and sputum had more severe 
asthma and poorer asthma control than noneosinophilic asthmatics, a finding which was validated in our 
prospective cohort. Our data show that isolated sputum eosinophilic inflammation is associated with impaired 
airway calibre and increased airway hyperresponsiveness compared with noneosinophilic asthmatics, while those 
combining both systemic and eosinophilic had further functional impairment, which is likely to partly contribute 
to worse asthma control and quality of life. Three-quarters of this group had an ACQ score >1.5 while only 10% 
had well-controlled asthma with an ACQ score <0.75. However, having an eosinophilic trait, whichever the 
compartment, is associated with a slightly raised proportion of atopy and higher serum IgE levels. 
 
FIGURE 1 Demographic, functional and inflammatory characteristics of patients according to their local and 
systemic eosinophil count. FEV1: forced expiratory volume in 1 s; FVC; forced vital capacity; BHR: bronchial 
hyperresponsiveness; FeNO: exhaled nitric oxide fraction; QoL: quality of life. 
 
 
FIGURE 2 Asthma control questionnaire (ACQ) score according blood and sputum eosinophil count. The 
presence of both local and systemic eosinophilic inflammation was associated with lower asthma control in the 
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FIGURE 3 Exhaled nitric oxide fraction (FeNO) levels in patients classified according to the presence and/or 
absence of blood and sputum eosinophilia. Patients exhibiting both local and systemic inflammation had the 
highest level of FeNO (n=508). The presence of uncontrolled eosinophilic inflammation either at local or 
systemic level was associated with intermediate levels of FeNO. The group of asthmatics showing no increase in 
eosinophilic inflammation had the lowest level of FeNO. Data are presented as mean ± SEM. 
 
 
It is important to note that patients in the group with blood and sputum eosinophilia had much higher sputum 
eosinophil counts compared with those with sputum eosinophilia alone. Beyond the categorical analysis, the 
extent of eosinophilic airway infiltration has to be taken into consideration. Our finding reinforces the role of 
airway eosinophilia in the loss of asthma control previously suggested on smaller sample of patients [13]. The 
intensity of blood eosinophilic inflammation in patients exhibiting diffuse eosinophilic inflammation was 
comparable to that of asthmatics with isolated blood eosinophilia, a group that was less severe. Moreover, there 
was no correlation between ACQ and blood eosinophil counts. This suggests that circulating eosinophils by 
themselves are not direct actors of asthma severity but are important in providing a pool of cells that can be 
attracted in the airways. 
Approximately 70% of patients exhibiting diffuse eosinophilic inflammation were receiving maintenance 
treatment with inhaled corticoids. While we could speculate that raising the dose of ICS in those receiving low to 
moderate doses would have resulted in a reduction of eosinophilic inflammation, it is noteworthy that 30% of the 
ICS treated patients were already receiving high doses. This highlights the relative resistance to corticoids in 
some patients and the need for complementary treatment to target eosinophils. Among the patients receiving 
high doses of inhaled corticoids, 53% exhibited either blood or sputum eosinophilia that could make them 
potential candidates for treatment with anti-interleukin-5 [25, 35]. A recent study has shown that omalizumab is 
more efficient in reducing exacerbation when patients express a Th2 profile including high blood eosinophil 
counts or FeNO levels [36]. Of course, as our study was a field study, we cannot rule out poor compliance in 
some patients, making the interpretation of corticoid resistance in these asthmatics difficult. 
Here, we deliberately chose to classify our patients according to pre-specified criteria, which were blood and 
sputum eosinophils. Our approach was therefore different from that used in hierarchical unsupervised cluster 
analysis. We do not deny the great interest of this type of cluster analysis in the emergence of clinical asthma 
phenotypes, but we believe that classifying asthmatics according to their eosinophilic profile is useful because 
sputum and blood eosinophils are good biomarkers to target treatment and predict response to corticoids or 
biologicals directed towards Th2 cytokines [37, 38]. Furthermore, it has recently been advocated that sputum 
eosinophils may be a valuable outcome in asthma drug trials [37]. How our asthma groups may fit with those 
found by others after cluster analysis remains to be determined [39-41]. There are some similarities coming out 
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of both approaches regarding the link between eosinophilia and sex. While females are the dominant sex among 
adult asthmatics, our data show that this is mainly accounted for by the noneosinophilic group even if females 
remained the predominant sex in those with isolated airway eosinophilic asthma. It is noteworthy that the 
proportion of males was significantly higher in those patients with an eosinophilic trait compared with their 
noneosinophilic counterpart and, in our study, it is striking that males even becomes the predominant sex in the 
case of diffuse eosinophilic inflammation. This is likely to reflect the different hormonal status and its effect on 
eosinophil biology. Few studies have evaluated the relationship between eosinophils and sex hormones. It seems 
that β-oestradiol significantly enhances eosinophil adhesion to human mucosal microvascular endothelial cells 
and their degranulation [42, 43]. 
 
 
TABLE 6 Retrospective cohort: demographic, functional and inflammatory characteristics of patients receiving 
high doses of corticosteroids (n = 144) 

























eosinophils ≥ 3% 
Subject n (%] 67 (47) 40 (28) 9(6) 28 (19) 
Males/females n 20/47 16/24 5/4 15/13 
Age years median (range) 52 (21-86) 59 (26-88) 62 (44-85) 52 (29-86) 
Age of onset %     
   <12years 25 35 0 30 
   12-40 years 33 30 50 40 
   ≥ 40 years 42 35 50 30 
Exacerbations per patient 
per year
||
 mean ± SD 
0.76 ± 1.06 0.95 ± 1.29 1.25 ± 1.17 3.52 ± 5.00*** 
FEV1 % predicted 77±17 77 ± 20 71±28 65 ±18** 
FEV1/FVC % 73 ± 11 68±13 70 ± 11 64 ± 9** 
ACQ score 2.57±1.96 1.97±1.25 3.19 ± 1.79 3.18 ±1.38 
AQLQ score 4.11 ± 1.39 4.52 ± 1.40 3.59 ± 1.47 3.50 ± 1.31 
FeNO ppb 14 (4-114) 30 (8-119)*** 10 (5-58) 55 (11-139]*** 
Blood eosinophils per mm
3
 160 (10-350) 225 (0-390)*** 465 (400-1030)*** 615 (400-3220]*** 
Sputum eosinophils % 0.25 (0-2.6) 8.4 (3-52.2)*** 0.4 (0-2.7) 22.3 (3.6-94.4]*** 
Data are presented as median (range) or mean + SD, unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital 
capacity; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; FeNO: exhaled nitric oxide fraction. #: 
comparator group; ||: during the year prior to the visit. *: p<0.05; **: p<0.01; ***: p<0.001. 
 
FIGURE 4 Correlation between Asthma Control Questionnaire (ACQ) score and a) sputum and b) blood 
eosinophil count when combining the prospective and retrospective cohorts (n=758). Asthma is considered 
uncontrolled if the ACQ score is >1.5. 
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By contrast, our data do not point to a peculiar association between obesity and noneosinophilic asthma as BMI 
was similar in all our groups of patients. 
Of interest is the fact that classic systemic inflammatory markers such as fibrinogen and C-reactive protein do 
not link at all with the severity of eosinophilic inflammation, a phenomenon that contrasts with what is usually 
seen in airway diseases exhibiting neutrophilic inflammation [44, 45]. 
One-third of asthmatics, approximately, exhibit dissociation between airway and systemic inflammation. The 
reasons why there may be discordant eosinophilic inflammation between blood and sputum remains unclear. In 
case of intense airway eosinophilic inflammation without blood eosinophilia, we could speculate about a massive 
local attraction due to the release of chemotactic agents without heavy stimulation of bone marrow. In patients 
with high blood eosinophil count and low sputum eosinophils, there could be a lack of transendothelial migration 
of eosinophils due to altered receptor expression or receptor down-regulation. An alternative explanation would 
be that the airway eosinophilic inflammation is masked by macrophage phagocytosis of eosinophils [46]. This 
could explain the intermittent eosinophilic phenotype [9] and the intermediate FeNO we found in this subgroup, 
as FeNO is a good surrogate marker for sputum eosinophilia [47]. 
Even if eosinophilic inflammation appears to be important in driving asthma severity, it has to be kept in mind 
that half of asthmatics did not display any sign of eosinophilic inflammation, among whom 59% remained 
poorly controlled. Of course, for those already receiving inhaled corticoids, it could be argued that some of them 
may have been eosinophilic prior to initiation of ICS treatment. The current literature suggests, however, that 
initiating or increasing the dose of inhaled corticoids in those noneosinophilic patients is probably useless for 
improving asthma control [22]. This points out the need to develop and test new drugs in this asthma phenotype. 
Clarithromycin was shown to slightly improve quality of life in refractory neutrophilic asthmatics and a recent 
study suggests that azithromycin may reduce exacerbation in patients with low blood eosinophil counts [48]. 
The main limitation of our study is the single time-point measurement that does not take into account the 
possible fluctuation of the patients from one group to another over time. Indeed, some patients were shown to be 
intermittently eosinophilic in their sputum, which may cause bias when dealing with a single measurement. 
However, we believe that looking at the relationship between ACQ score and sputum eosinophils based on one 
single evaluation remains valid as ACQ score reflects disease control on a short time period (1 week), a period 
over which sputum eosinophil count was found to be reproducible [49]. 
Exacerbation rate, which was clearly higher in the group with combined eosinophilic inflammation, must be 
considered cautiously as it was based on history taking and it is not always easy to disentangle what was justified 
by genuine asthma worsening or by a flare up of sinusitis with cough. Nevertheless, the fact that the prospective 
cohort confirmed the proportion of eosinophilic subgroups and the exacerbation rates found in the retrospective 
cohort is quite reassuring of the validity of our classification. Of interest also is the fact that exacerbation rate 
decreased on average by 42% in the year after the visit to our asthma clinic, suggesting that what the clinician 
decided based on a comprehensive investigation has had an impact on long-term asthma control. Naturally, this 
is an observational finding that does not obey the tight criteria of randomised controlled trials and our finding 
has to be confirmed in randomised trials comparing different management strategies. 
Our proportion of eosinophilic asthma is greater than that found by MCGRATH et al. [9], as they only found 
eosinophilic asthma in 17-36% of patients. However, their study recruited patients highly selectively, as is 
usually the case in clinical drug trials, thereby excluding quite a proportion of patients seen in clinical practice 
(i.e. smokers, those poorly reversible to β2-agonists and those with comorbidity), which was not the case in our 
field study. Of course, we can also speculate that compliance to ICS was better in patients described by 
MCGRATH et al. [9], which may have also resulted in lower proportion of eosinophilic asthma. It is worth noting 
that our proportion of noneosinophilic versus eosinophilic asthma based on sputum analysis is rather similar to 
what was reported in another field study [3]. 
 
Conclusion 
Concomitant systemic and bronchial eosinophilic inflammation contribute to poor asthma control. As there was 
dissociation between systemic and airway eosinophilic inflammation in 30% of patients, assessment of 
inflammation in both airways and peripheral blood provides additional information about asthma status. We 
believe our classification may be valid to start intervention studies using drugs mainly targeting either the 
airways or the blood compartment according to the patient's profile. 
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